CD44 is a widely accepted marker of bladder cancer stem cells, we employed an emerging technology, mass cytometry TOF (CyTOF) which is novel single-cell analysis technology with the ability to analyze more than 35 unique parameters on a million cells, to analyze the cancer stem cell-like population between UBC9-high and UBC9-low bladder cancers samples. The gene discussed is UBE2I; the disease is urinary bladder carcinoma.